PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On June 9, 2017, Dr. Adam Koppel, a member of the board of
directors (the Board) of PTC Therapeutics, Inc. (the Company),
notified the Company of his resignation from the Board effective
immediately.
Dr. Koppel has informed the Company that his decision is based on
his need to focus on commitments to his principal work activities
and was not due to any disagreement with the Company.
Item 5.07 – Submission of Matters to a Vote of Security Holders
PTC Therapeutics, Inc. (the Company) held its Annual Meeting of
Stockholders on June 9, 2017. The final results for the votes
regarding each proposal are set forth below.
The stockholders of the Company elected two Class I directors,
each to hold office until the Companys 2020 annual meeting of
stockholders or until his successor has been duly elected and
qualified, as follows:
Director
For
Withheld
Broker
Non-Votes
Stuart W. Peltz, Ph.D.
29,043,013
75,347
5,544,983
Jerome B. Zeldis, M.D., Ph.D.
21,653,839
7,464,521
5,544,983
The appointment of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017 was ratified by the Companys stockholders with
25,797,448 votes For, 260,455 votes Against, and 4,744 votes
Abstained.
The non-binding advisory proposal on named executive officer
compensation was approved by the Companys stockholders with
19,506,394 votes For, 985,329 votes Against, 25,941 votes
Abstained, and 5,544,983 broker non-votes.


About PTC THERAPEUTICS, INC. (NASDAQ:PTCT)

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.